In This Article:
-
The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has backed using AstraZeneca Plc's (NASDAQ: AZN) COVID-19 drug treatment.
-
AstraZeneca said the EMA had backed Evusheld as a treatment for adults and adolescents with COVID who do not need supplemental oxygen and are at increased risk of worsening their disease.
-
The antibody cocktail was previously only approved as a preventative treatment for people with compromised immune systems who see little or no benefit from vaccines.
-
Related: AstraZeneca Scores Its First Global Approval For Antibody Evusheld As COVID-19 Treatment.
-
The EMA also endorsed Beyfortus (nirsevimab) to prevent respiratory syncytial virus (RSV) lower respiratory tract disease in infants.
-
Related: AstraZeneca-Sanofi's Nirsevimab Shows 75% Efficacy Against RSV In Healthy Infants.
-
AstraZeneca is developing Beyfortus along with Sanofi SA (NASDAQ: SNY).
-
The pharma giant also said that if Beyfortus is approved, it will become the first protective option for newborn and infant population against RSV lower respiratory tract disease.
-
Price Action: AZN shares are up 1.82% at $59.20 during the premarket session on the last check Friday.
See more from Benzinga
Don't miss real-time alerts on your stocks - join Benzinga Pro for free! Try the tool that will help you invest smarter, faster, and better.
© 2022 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.